Lecture Details - Overview

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Algorithms for the Treatment of Metastatic Breast Cancer: Current Data on and Implications for New Trials in Early-Stage Breast Cancer

Release Date: October 31, 2008| Expiration Date: October 31, 2009
Oct 3, 2008, New York, NY

Lecture Overview

With an increasing number of treatment options for metastatic breast cancer, physicians are faced with the challenge of understanding which options might be best for individual patients. The Algorithms for the Treatment of Metastatic Breast Cancer: Current Data on and Implications for New Trials in Early-Stage Breast Cancer symposium is designed to educate physicians about recent data on the treatment of patients with breast cancer who might be facing more challenging clinical situations, including prior exposure to common cytotoxic agents such as taxanes, anthracyclines, and/or antimetabolites; disease that is both hormone receptor and HER2 negative; and disease that has relapsed after prior HER2-targeted therapy. This symposium will also describe the implications of recent data on epothilones and novel taxanes for ongoing and planned trials in patients with early-stage breast cancer.

This educational program is directed toward physicians with an interest in the treatment of breast cancer. Nurses, physician assistants, and other individuals interested in the treatment of breast cancer are also invited to participate.

At the conclusion of this activity, you should be able to:

  • Describe the role of novel taxane formulations and epothilones in the treatment algorithm for metastatic breast cancer within the context of specific patient scenarios and breast cancer subtypes
  • Discuss ongoing trials of and the clinical rationale for the integration of novel taxanes and epothilones into the treatment of early-stage breast cancer

Instructions for Participation

  1. Read the following information before beginning the educational activity.
  2. Complete the Pretest.
  3. View and study all Flash video presentations.
  4. Complete the CME test.
  5. Answer the evaluation questions.
  6. After successful completion of the CME test and evaluation, you will receive your certificate online.
  • CME credit will be granted for online participation only.
View the Activity
You will be asked to login
or create an account.

Educational Grants

An educational grant for this activity was provided by:


  1. Bristol-Myers Squibb